Dientamoeba fragilis is a commonly encountered trichomonad which has been implicated as a cause of gastrointestinal disease in humans. Despite the frequency of reports recording infections with this parasite, little research has been undertaken in terms of antimicrobial susceptibility. The aim of this study was to evaluate the susceptibility of D. fragilis to several commonly used antiparasitic agents: diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, secnidazole, ronidazole, tetracycline, and tinidazole. Antibiotic susceptibility testing was performed on four clinical strains of D. fragilis, designated A, E, M, and V, respectively. Molecular testing followed, and all strains were determined to be genotype 1. The activities of antiprotozoal compounds at concentrations ranging from 2 g/ml to 500 g/ml were determined via cell counts of D. fragilis trophozoites grown in dixenic culture. Minimum lethal concentrations (MLCs) were as follows: ornidazole, 8 to 16 g/ml; ronidazole, 8 to 16 g/ml; tinidazole, 31 g/ml; metronidazole, 31 g/ml; secnidazole, 31 to 63 g/ml; nitazoxanide, 63 g/ml; tetracycline, 250 g/ml; furazolidone, 250 to 500 g/ml; iodoquinol, 500 g/ml; paromomycin, 500 g/ml; and diloxanide furoate, >500 g/ml. This is the first study to report the profiles of susceptibility to a wide range of commonly used treatments for clinical isolates of D. fragilis. Our study indicated 5-nitroimidazole derivatives to be the most active compounds in vitro against D. fragilis.
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I
nitially described by Jepps and Dobell (18) , Dientamoeba fragilis is a protozoan parasite implicated as a cause of gastrointestinal diseases in both developed and developing regions of the world. Infection rates typically range from 0.5% to 16%, with higher rates seen in outbreaks or where personal hygiene is suboptimal (3, 17, 21, 26) . The protozoan is recognized to cause chronic infections. In a prospective study, 6,750 patients were screened for D. fragilis, and 32% of patients presented with chronic symptoms (31) , including abdominal pain, diarrhea, and nausea. Some authors have linked D. fragilis to irritable bowel syndrome (IBS)-like symptoms (4, 32) .
Currently, a majority of evidence supports the pathogenic potential of D. fragilis (5) . As such, it suggests the need for not only the correct diagnosis but also appropriate treatment (29, 30) . The parasite responds to a number of antimicrobial compounds, with studies reporting the complete resolution and elimination of parasites following therapy with iodoquinol (8) metronidazole (24) , paromomycin (13) , and secnidazole (16) . In an Australian study, complete resolution and eradication of the organism were observed for most patients following treatments with iodoquinol, paromomycin, or combination therapy, while treatment relapses/ failures were recorded only with the use of metronidazole (29) . It is of note that there are no current treatment guidelines for D. fragilis infections in place.
While D. fragilis can be readily cultured from clinical samples (4), long-term cultures are notoriously difficult to maintain (12) , and this has hampered the in vitro study of this organism, including susceptibility testing. The objective of this study was to determine the in vitro susceptibility of a number of clinical isolates of D. fragilis to diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, ronidazole, secnidazole, tetracycline, and tinidazole. The results obtained will assist in the development of recommendations for the treatment of dientamoebiasis.
MATERIALS AND METHODS
Parasite culture. Four strains of D. fragilis, A, E, M, and V, were isolated and propagated in vitro using Loeffler slopes, as described by Barratt et al. (4) .
Antimicrobial agents/susceptibility testing. Susceptibility testing was performed for the following agents: diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, ronidazole, secnidazole, tetracycline, and tinidazole. Metronidazole (Pfizer, NSW, Australia) in liquid form at 5 mg/ml was used as a stock solution and diluted with phosphate-buffered saline (PBS) buffer to cover a concentration range of 2 g/ml to 500 g/ml by doubling dilution. Tetracycline (Bioline, Alexandria, NSW, Australia) suspended in 90% ethanol at 12.5 mg/ml was diluted to 5 mg/ml and diluted in the same manner described for metronidazole. Ornidazole (Queensland Institute of Medical Research) in powder form was dissolved in 50% ethanol to 5 mg/ml and diluted thereafter. Paromomycin sulfate (Sigma-Aldrich, Sydney, NSW, Australia) and diloxanide furoate, furazolidone, iodoquinol, nitazoxanide, ronidazole, secnidazole, and tinidazole (all from West Lindfield Compounding Chemist, NSW, Australia) in powder form were suspended in 10% ethanol to make stock solutions at 5 mg/ml. Further dilutions were prepared by doubling dilution to cover from 2 g/ml to 500 g/ml. One milliliter of the respective dilutions was added to Loeffler slopes supplemented with rice starch and PBS overlay to contain a total liquid volume of 8 ml. A control consisting of 1 ml of 10% ethanol diluted into the same volume was performed in duplicate for all drugs in powder form to rule out any inhibitory effects on D. fragilis. As PBS buffer was used as a diluent for metronidazole and tetracycline, the same volume of PBS buffer was used as a control.
The cell concentration was determined using Kova slides viewed under a phase-contrast microscope at a magnification of ϫ400. As a decline in numbers of D. fragilis trophozoites occurs in negative controls after 92 h postexperiment, susceptibility testing with each compound was performed for only 4 days. Minimal lethal concentrations (MLCs) were determined to be the concentration of the drug at which no trophozoites were observed over the treatment period.
Characterization of bacterial flora and susceptibility testing from xenic culture. The bacterial flora present in dixenic cultures was characterized and identified. Supernatants from D. fragilis cultures were inoculated onto the following media: Columbia horse blood agar, Brilliance UTI agar, MacConkey agar, Sabouraud's agar, and anaerobic medium (Thermofisher Scientific Australia Pty Ltd., Scoresby, Victoria, Australia). The aerobic medium plates were incubated at 35°C for 24 to 48 h under aerobic conditions, while the anaerobic medium plates were incubated for 48 to 72 h under anaerobic conditions using an Anoxomat Mark II system (Mart Microbiology) with the following gas composition: 0.16% O 2 , 5% H 2 , 10% CO 2 , and 85% N 2 . All bacterial isolates were identified to species level using routine bacteriological procedures, including traditional phenotypic testing, biochemical testing, and RapID API strips (Biomeriéux, Baulkham Hills, Australia), according to the manufacturer's instructions.
Bacterial 16S rRNA gene sequencing. Cultured clinical isolates were used for DNA extraction using a QIAamp DNA minikit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. PCR amplifications were performed using pure-Taq Ready-To-Go (Amersham Biosciences, Rydalmere, Australia) PCR beads (each containing ϳ1.5 units Taq DNA polymerase, 10 mM Tris-HCl at pH 9, 50 mM KCl, 1.5 mM MgCl 2 , 200 mM each deoxynucleoside triphosphate, and stabilizers, including bovine serum albumin), 1.0 l of genomic DNA, and 0.5 M universal primers, forward primer with the sequence of 5=-AGAGTTTGATCMTG GCTCAG, and reverse primer with the sequence of 5=-AAGGAGGTGW TCCARCC. The following thermocycling profile was used: 3 min denaturation at 94°C and 30 cycles of 1 min at 94°C, 1.5 min at 57°C, and 2 min at 72°C. Purification of PCR products was performed using QIAquick PCR purification kits (Qiagen), according to the manufacturer's instructions. Sequencing of purified bacterial DNA was then performed by the Australian Genome Research Facility (AGRF). The sequence data were then compared to other bacterial sequences using BLASTN (34) and the GenBank database (http://www.ncbi.nlm.nih.gov/BLAST/).
After the completion of susceptibility testing, the bacterial flora was again fully characterized and checked for the presence of bacterial species unaffected by the treatments.
Genotyping of D. fragilis isolates. Genotyping of the D. fragilis isolates were performed as previously described by Stark et al. (31) .
RESULTS

D. fragilis genotyping.
All D. fragilis isolates were identified to be genotype 1 by 18S ribosomal DNA analysis (GenBank accession number AY730405).
Bacterial flora identified from four dixenic cultures. The bacterial flora identified from the dixenic cultures is shown in Table 1 .
MLCs. The results are shown in Tables 2 to 9 . Briefly, mean MLC values for the compounds were as follows: ornidazole, 8 to 16 g/ml; ronidazole, 8 to 16 g/ml; tinidazole, 31 g/ml; metronidazole, 31 g/ml; secnidazole, 31 to 63 g/ml; nitazoxanide, 63 g/ml; tetracycline, 250 g/ml; furazolidone, 250 to 500 g/ml; iodoquinol, 500 g/ml; paromomycin, 500 g/ml; and diloxanide furoate, Ͼ500 g/ml (as minimal or no effects were found with diloxanide furoate, iodoquinol, and paromomycin, tables for these compounds have been excluded). Minor differences in the MLCs between the clinical isolates were observed for a number of drugs, including furazolidone, nitazoxanide, ornidazole, ronidazole, and secnidazole, with isolate V showing slightly higher MLCs than those of the other isolates in general (Tables 2 and 4 
to 7).
Bacterial flora identified posttreatment. The bacterial flora identified posttreatment are presented in Table 1 .
(i) Ronidazole. At the concentrations above the MLC, ronidazole treatment led to the removal of the majority of the bacterial flora, while it left Escherichia coli, Pseudomonas aeruginosa, Clostridium spp., and Bacteroides fragilis unaffected.
(ii) Tinidazole. Tinidazole treatment led to the removal of Eubacterium limosum, Collinsella aerofaciens, Veillonella spp., and Parabacteroides distasonis, while it left E. coli, P. aeruginosa, Clostridium spp., Bacteroides spp., Peptostreptococcus spp., and Eggerthella lenta unaffected.
(iii) Ornidazole. At ornidazole concentrations above the MLC, E. coli, P. aeruginosa, and B. fragilis were unaffected by the treatment, while ornidazole led to the removal of Clostridium spp., E. limosum, C. aerofaciens, Veillonella spp., Bacteroides ovatus, Pep- A drug concentration of 0 g/ml refers to negative control, where 10% ethanol was added into the medium. A drug concentration of 0 g/ml refers to negative control, where 10% ethanol was added into the medium.
Nagata et al. .18) 0 (0) 1 (0) 1.6 (0.23) A drug concentration of 0 g/ml refers to negative control, where phosphate-buffered saline, used for dilution, was added into the medium.
centrations for iodoquinol, paromomycin, tetracycline, and metronidazole were determined to be 128, 16, 32, and 32 g/ml, respectively (10), in contrast to our data, which were 500, 500, 250, and 31 g/ml, respectively. The previous study used the D. fragilis strain ATCC 30948 (genotype 2), which has not been found to be associated with gastrointestinal diseases to date and is rarely encountered in human samples (11, 25, 28) . While the majority of studies have shown genotype 1 in nearly all cases (6, 31, 33, 36) , testing of this genotype may be more appropriate in terms of clinical significance and may be a possible reason for the different MLC values between the two studies. The true complexity of the bacterial flora contained within these clinical isolates of D. fragilis is summarized in Table 1 . Elimination of certain species and/or the majority of the bacterial flora present in the cultures may indirectly result in detrimental effects to the D. fragilis trophozoites, as the parasite has long been known to utilize them as a food source. However, it was observed that the treatments did not affect the majority of the bacterial flora present. This supports the notion that elimination of D. fragilis in these is the result of the antiparasitic effects of the drug and not due to the antibacterial effects on the bacterial populations.
The results of this study show that the inhibitory effects of a number of antimicrobials currently used as recommended treatments, including iodoquinol, paromomycin, and tetracycline, make them inappropriate for treatment of D. fragilis infections. The use of newer antiprotozoal compounds with far fewer known side effects or combination therapies derived from current treatment options for D. fragilis infections appears to be a viable option for consideration. In summary, the data presented here indicated that the use of 5-nitroimidazoles is the most effective option for treating D. fragilis infections, with ornidazole and ronidazole being the most active in vitro compounds.
